The drug that first changed HIV from a death sentence to a manageable condition was not a single pill but a strategy: HAART, or Highly Active Antiretroviral Therapy, a triple-drug combination introduced in 1996 that could durably suppress the virus in ways no single medication had managed before. Before HAART, an AIDS diagnosis meant most patients had one to two years left. After its introduction, U.S. AIDS-related deaths declined by 47 percent in a single year, and by 1996, AIDS was no longer the leading cause of death among young American adults. That shift — from writing eulogies to refilling prescriptions — remains one of the most dramatic reversals in modern medicine.
But the story did not begin in 1996, and it has not ended there. The road started with AZT in 1987, a repurposed cancer drug that bought patients time but could not hold the virus back alone. It runs through the protease inhibitors of the mid-1990s, the one-pill-a-day regimens of the 2010s, and now reaches into a future where a single injection every six months can prevent HIV infection entirely. For readers of a brain health and dementia care site, this history matters more than you might expect — HIV-associated neurocognitive disorders remain a concern even for those on effective treatment, and the lessons learned from HIV drug development have reshaped how researchers approach other chronic neurological conditions. This article traces the full arc: from the desperate early years, through the breakthrough drugs and the science behind them, to the modern treatment landscape and what it means for long-term brain health and aging with HIV.
Table of Contents
- What Was the First Drug That Changed HIV From a Certain Death Sentence?
- How HAART Turned a Fatal Diagnosis Into a Chronic Condition
- From Dozens of Pills to One a Day — How Modern HIV Treatment Evolved
- Twice-Yearly Injections and the New Frontier of HIV Prevention
- HIV, the Brain, and Why This Matters for Dementia and Cognitive Health
- Life Expectancy With HIV — How Close to Normal?
- Is a Cure on the Horizon?
- Conclusion
- Frequently Asked Questions
What Was the First Drug That Changed HIV From a Certain Death Sentence?
The first FDA-approved drug to treat HIV was AZT, known generically as zidovudine, which received approval on March 20, 1987 — a record 20 months after clinical trials began. AZT had an unlikely origin. It was originally synthesized in 1964 as a potential cancer therapy, proved ineffective for that purpose, and sat on a shelf for two decades until the National Cancer Institute included it in a screening program for drugs that might work against the newly identified human immunodeficiency virus. The pivotal trial enrolled 282 HIV-positive patients and produced results so striking that researchers halted it early on ethical grounds. In the AZT group, 99.3 percent of patients survived the roughly four-month study period, compared to 86.1 percent in the placebo group.
For a disease that had been untouchable, those numbers felt like a miracle. But AZT had a critical limitation: used alone, it was a stopgap. HIV mutated rapidly and developed resistance to monotherapy, meaning the virus would eventually find its way around the drug. Patients on AZT alone often saw their health improve temporarily, only to decline again months later. The drug extended lives, but it did not save them — not yet, and not by itself.
How HAART Turned a Fatal Diagnosis Into a Chronic Condition
The genuine turning point came between late 1995 and 1996, when a new class of drugs — protease inhibitors — entered the picture. Saquinavir, manufactured by Roche, became the first protease inhibitor approved by the FDA in December 1995. Indinavir from Merck and ritonavir from Abbott followed shortly after in early 1996. These drugs attacked HIV at a different stage of its life cycle than AZT and its relatives, and researchers quickly discovered that combining two older drugs (nucleoside reverse transcriptase inhibitors, or NRTIs) with a protease inhibitor created a triple-drug regimen the virus could not easily outmaneuver. This approach became known as HAART — Highly Active Antiretroviral Therapy. The impact was immediate and measurable.
U.S. AIDS deaths had exceeded 40,000 in 1995. After HAART’s widespread introduction, the CDC’s February 28, 1997 Morbidity and Mortality Weekly Report documented the first substantial decline in AIDS deaths in the entire history of the epidemic — a 47 percent drop. However, HAART was not without serious downsides. Early regimens required patients to take dozens of pills per day on rigid schedules, often with severe side effects including lipodystrophy, kidney stones, and metabolic complications. Missing doses risked breeding drug-resistant strains. For many patients, especially those without stable housing or reliable access to healthcare, adherence was a daily battle that the drugs alone could not solve.
From Dozens of Pills to One a Day — How Modern HIV Treatment Evolved
The early HAART regimens worked, but they demanded an almost punishing level of discipline. Some patients took upwards of 20 pills a day, timed to meals, spaced at precise intervals. The pharmaceutical industry spent the next two decades solving that problem. By the late 2000s and into the 2010s, fixed-dose combination pills began consolidating entire regimens into a single tablet taken once daily.
More than 30 antiretroviral drugs are now available across multiple drug classes — NRTIs, NNRTIs, protease inhibitors, integrase inhibitors, and the newest addition, capsid inhibitors — giving doctors a deep toolkit to tailor treatment to individual patients. One of the most notable advances has been Cabenuva, a long-acting injectable combination of cabotegravir and rilpivirine. Instead of daily pills, patients receive an injection monthly or every two months. For people who struggle with daily adherence, who face stigma around pill-taking, or who simply want their condition to occupy less mental space in their lives, this kind of regimen change is not trivial — it is transformative. The shift from emergency medicine to convenience medicine reflects just how far HIV treatment has come, though it also raises questions about cost and access that remain unresolved for many communities.
Twice-Yearly Injections and the New Frontier of HIV Prevention
In June 2025, the FDA approved lenacapavir, marketed by Gilead under the brand name Yeztugo, as the first twice-yearly injectable for HIV prevention. The clinical data behind the approval was extraordinary. In the PURPOSE 1 trial, zero HIV infections occurred among 2,134 participants — 100 percent efficacy, outperforming daily oral Truvada. The PURPOSE 2 trial, conducted in a more diverse population, recorded only 2 infections among 2,179 participants, translating to 99.9 percent effectiveness. The dosing schedule — a 927 mg injection plus an oral loading dose, followed by one injection every six months — essentially reduces HIV prevention to a twice-yearly doctor’s visit.
Lenacapavir had previously been approved in 2022 under the brand name Sunlenca for treatment-experienced patients with multidrug-resistant HIV, so its safety profile was already established. The tradeoff, as with many breakthrough drugs, is cost and access. In wealthy nations, the drug carries a significant price tag. However, by September 2025, partnerships involving the Clinton Health Access Initiative, Unitaid, and the Gates Foundation had secured generic manufacturing agreements to provide lenacapavir at roughly $40 per patient per year in 120 low- and middle-income countries. That price difference — from thousands of dollars to $40 — illustrates both the promise and the inequity baked into global pharmaceutical markets.
HIV, the Brain, and Why This Matters for Dementia and Cognitive Health
Even with viral suppression, HIV’s relationship with the brain is not fully resolved. HIV-associated neurocognitive disorders, collectively known as HAND, affect a meaningful percentage of people living with HIV, even those on effective antiretroviral therapy. The virus can cross the blood-brain barrier early in infection, establishing reservoirs in the central nervous system that are difficult to reach with standard treatment. While severe HIV dementia has become rare thanks to effective ART, milder forms of cognitive impairment — difficulty with concentration, memory, and executive function — persist in a subset of patients.
For caregivers and families already navigating dementia or age-related cognitive decline, this intersection matters. As HIV has become a manageable chronic condition, the population of people aging with HIV has grown substantially. A person diagnosed at 30 in 2000 may now be in their mid-50s, facing the same age-related neurological risks as the general population — but with the added variable of decades of viral exposure and antiretroviral medication. Research into whether long-term ART itself contributes to or protects against neurodegeneration is ongoing, and the answers are not yet clear. What is clear is that brain health monitoring should be part of routine HIV care, particularly for older adults.
Life Expectancy With HIV — How Close to Normal?
A 2022 cohort study following 200,000 people with HIV across Europe and North America found that those on long-term antiretroviral therapy with high CD4 counts had lifespans similar to the general population. That finding would have been unthinkable in 1990.
The global impact has been equally significant: average life expectancy in Sub-Saharan Africa rose from 56 years in 2010 to 61 years by 2023, a gain driven largely by progress against HIV and AIDS, according to a UN global report. These are not abstract statistics — they represent millions of people who are alive, working, raising families, and growing old because of drugs that did not exist three decades ago.
Is a Cure on the Horizon?
No widely available cure for HIV exists as of 2026, and honesty about that is important. A handful of individuals have achieved long-term remission through experimental procedures, most notably stem cell transplants using donor cells carrying the CCR5-delta32 mutation, which blocks HIV’s primary entry point into cells.
These cases are remarkable but not scalable — stem cell transplants carry serious risks and are not a realistic option for the roughly 39 million people living with HIV worldwide. The most promising avenue for a broader solution lies in broadly neutralizing antibodies, or bNAbs, which are under intensive study as a potential path to functional cure or sustained remission without daily antiretroviral therapy. The trajectory of HIV treatment — from nothing, to AZT, to HAART, to twice-yearly injections — gives reason for cautious optimism, but the history also teaches that breakthroughs take time, and the distance between a laboratory result and a clinic-ready treatment can be measured in decades.
Conclusion
The transformation of HIV from a death sentence to a manageable chronic condition stands as one of the most significant achievements in the history of medicine. It required not one drug but a succession of them — AZT buying time in 1987, protease inhibitors enabling HAART in 1996, fixed-dose combinations simplifying daily life in the 2000s, and long-acting injectables redefining what treatment and prevention look like today. Each step reduced the burden on patients and brought life expectancy closer to normal.
For those concerned with brain health and dementia care, the HIV story carries particular relevance. An aging population of people living with HIV means new questions about long-term cognitive health, drug interactions, and the intersection of viral disease with neurodegeneration. Caregivers, clinicians, and families should understand that effective HIV treatment has given millions of people the gift of growing old — and with that gift comes the same cognitive health challenges, and sometimes additional ones, that the broader aging population faces. Staying informed about both HIV management and brain health is no longer optional for anyone providing comprehensive care to older adults.
Frequently Asked Questions
What was the first drug approved to treat HIV?
AZT (zidovudine) was approved by the FDA on March 20, 1987. Originally developed in 1964 as a cancer treatment, it was repurposed after showing effectiveness against HIV in clinical trials. However, it could not control the virus long-term when used alone.
What does HAART stand for and why was it so important?
HAART stands for Highly Active Antiretroviral Therapy, a triple-drug combination strategy introduced in 1996 that combined two NRTIs with a protease inhibitor. It was the first approach that could durably suppress HIV replication, leading to a 47 percent decline in U.S. AIDS deaths within a year of its introduction.
Can people with HIV now live a normal lifespan?
A 2022 cohort study of 200,000 people with HIV in Europe and North America found that those on long-term antiretroviral therapy with high CD4 counts had lifespans similar to the general population. However, outcomes depend heavily on early diagnosis, consistent treatment, and access to healthcare.
Does HIV affect brain health even when the virus is controlled?
Yes. HIV-associated neurocognitive disorders can occur even in people on effective antiretroviral therapy. While severe HIV dementia has become rare, milder cognitive impairments involving memory, concentration, and executive function persist in some patients, making brain health monitoring an important part of long-term HIV care.
Is there a cure for HIV?
As of 2026, no widely available cure exists. A small number of individuals have achieved long-term remission through stem cell transplants using CCR5-delta32 donor cells, but this is not scalable. Broadly neutralizing antibodies are under active research as a potential path to functional cure.
What is the most advanced HIV prevention method available?
Lenacapavir (Yeztugo), approved by the FDA in June 2025, is the first twice-yearly injectable for HIV prevention. In clinical trials, it demonstrated 100 percent efficacy in one study and 99.9 percent effectiveness in another, requiring only one injection every six months.
